Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.51 - $1.27 $116,777 - $290,799
-228,976 Reduced 71.04%
93,354 $84,000
Q1 2024

May 15, 2024

BUY
$0.8 - $1.51 $80,421 - $151,795
100,527 Added 45.32%
322,330 $380,000
Q4 2023

Feb 14, 2024

BUY
$0.48 - $1.08 $99,797 - $224,544
207,912 Added 1496.74%
221,803 $201,000
Q3 2023

Nov 14, 2023

SELL
$0.78 - $1.82 $247,917 - $578,474
-317,843 Reduced 95.81%
13,891 $11,000
Q2 2023

Aug 14, 2023

SELL
$0.98 - $1.53 $940,221 - $1.47 Million
-959,410 Reduced 74.31%
331,734 $398,000
Q1 2023

May 15, 2023

BUY
$0.96 - $2.92 $1.15 Million - $3.49 Million
1,196,672 Added 1266.69%
1,291,144 $1.63 Million
Q4 2022

Feb 14, 2023

SELL
$1.74 - $12.87 $87,729 - $648,892
-50,419 Reduced 34.8%
94,472 $205,000
Q3 2022

Nov 14, 2022

BUY
$7.21 - $14.88 $354,688 - $732,006
49,194 Added 51.41%
144,891 $1.74 Million
Q3 2022

Nov 14, 2022

BUY
$7.21 - $14.88 $354,688 - $732,006
49,194 Added 51.41%
144,891 $1.74 Million
Q2 2022

Aug 16, 2022

BUY
$5.97 - $9.97 $382,115 - $638,139
64,006 Added 201.97%
95,697 $801,000
Q1 2022

May 17, 2022

BUY
$8.44 - $12.49 $31,447 - $46,537
3,726 Added 13.32%
31,691 $275,000
Q4 2021

Feb 15, 2022

SELL
$10.12 - $14.07 $202,764 - $281,906
-20,036 Reduced 41.74%
27,965 $317,000
Q3 2021

Nov 16, 2021

BUY
$7.25 - $13.23 $201,434 - $367,582
27,784 Added 137.43%
48,001 $603,000
Q2 2021

Aug 16, 2021

BUY
$8.0 - $9.75 $161,736 - $197,115
20,217 New
20,217 $164,000
Q1 2021

May 18, 2021

SELL
$8.63 - $10.94 $280,345 - $355,385
-32,485 Closed
0 $0
Q4 2020

Feb 17, 2021

SELL
$8.3 - $13.59 $49,841 - $81,607
-6,005 Reduced 15.6%
32,485 $314,000
Q3 2020

Nov 17, 2020

BUY
$11.3 - $14.75 $434,937 - $567,727
38,490 New
38,490 $477,000

Others Institutions Holding GOSS

About Gossamer Bio, Inc.


  • Ticker GOSS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,954,000
  • Market Cap $93M
  • Description
  • Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...
More about GOSS
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.